1. Akhondzadeh, S., Erfani, S., Mohammadi, M. R., Tehrani-Doost, M., Amini, H., Gudarzi, S. S., et al. (2004). Cyproheptadine in the treatment of autistic disorder: A double-blind placebo-controlled trial. Journal of Clinical Pharmacy & Therapeutics, 29(2), 145–150.
2. Akhondzadeh, S., Fallah, J., Mohammadi, M. R., Imani, R., Mohammadi, M., Salehi, B., et al. (2010). Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34, 32–36.
3. Aman, M. G., Singh, N. N., & Stewart, A. W. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiencies, 89, 485–491.
4. Aman, M. G., Lam, K. S., & Collier-Crespin, A. (2003). Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders, 33, 527–534.
5. Anderson, L. T., Campbell, M., Grega, D. M., Perry, R., Small, A. M., & Green, W. H. (1984). Haloperidol in infantile autism: Effects on learning and behavioral symptoms. American Journal of Psychiatry, 141(10), 195–202.